Survival outcome (overall survival [OS]) data from four centers with prospectively collecting data on patients with PTCL in the United States, Europe, and Korea were acquired. Data were collected from 1) Memorial Sloan Kettering Cancer Center (MSKCC) for 171 patients who were treated at their institution between June 1997 to July 2011, 2) University of Nebraska Medical Center (UNMC) provided data for 67 patients diagnosed between July 1, 1984 and May 17, 2010 who were part of the Nebraska Lymphoma Study Group, 3) Groupe d’Etude des Lymphomes de l’Adulte (GELA) provided information on 117 patients whose first-line treatment was administered under the four clinical trials conducted between December 1997 and April 2008, and 4) The Samsung Medical Center (SMC) in South Korea provided data on 504 patients based on a retrospectively characterized databased collected between 1995 and 2007 and a prospectively maintained database initiated in 2008. In total, data from 859 patients were collected from the four sites.
A total of 386 patients (including 69, 44, 110, and 163 patients collected from MSKCC, UNMC, GELA, and SMC databases, respectively) were identified from these four databases based on the following specific selection criteria: 1) histologies consistent with the inclusion criteria of PROPEL; 2) patients who received at least two lines of prior therapy (ie, the second line of therapy would match with patients receiving pralatrexate on PROPEL, which required one line of prior therapy); and 3) patients who had not received pralatrexate. The efficacy data were not part of the criteria to select patients for inclusion in the historical database.
A total of 386 patients (including 69, 44, 110, and 163 patients collected from MSKCC, UNMC, GELA, and SMC databases, respectively) were identified from these four databases based on the following specific selection criteria: 1) histologies consistent with the inclusion criteria of PROPEL; 2) patients who received at least two lines of prior therapy (ie, the second line of therapy would match with patients receiving pralatrexate on PROPEL, which required one line of prior therapy); and 3) patients who had not received pralatrexate. The efficacy data were not part of the criteria to select patients for inclusion in the historical database.
